Breakthrough Fusion Gene Map Technology Announcement Takes Hold of $15 Billion Leukemia Treatment Market

This Biotech has been flying under the radar, now may be the best time to start your research on Avalon GloboCare Corp. (NASDAQ: ALBT)

Price Targets


1D -> 1 WK


< 1 WK


1-2 WKS


> 2 WKS

Potential support at 3.05

The Milestone Cancer Therapy Announcement We’ve Been Waiting For

“We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio”

David Jin, M.D., Ph.D.

President and Chief Executive Officer of Avalon GloboCare

Avalon GloboCare Corp., a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins”.

The “QTY Code”, is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly enhancing the solubility of designer peptides and proteins, therefore expanding the arsenal of selected therapeutic targets against cancers and other diseases. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT). This is one of 16 jointly filed patent applications with key strategic partners.

Microscope with flasks


Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules

7 Key Reasons Why Avalon GloboCare Corp. (NASDAQ: ALBT) Could Witness Unstoppable Growth Throughout 2023

UPSIDE POTENTIAL: In less than a month’s time, shares of Avalon GloboCare Corp. (NASDAQ: ALBT) climbed over 101% after bouncing off its 52-week low of $3.00 set on 12/09/2022, reaching an intraday high of $6.05 on 1/03/2023, according to the price history available at What’s even more interesting is that the technical analysis tools on indicate shares of (ALBT) have a 200-day moving average of $13.20.

MAKING HEADLINES: As a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, Avalon GloboCare Corp. (Nasdaq: ALBT) announced it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.

GROWING MARKET: The global leukemia therapeutics market was expected to grow from $13.88 billion in 2021 to $15.27 billion in 2022 at a compound annual growth rate (CAGR) of 10.07%. The leukemia therapeutics market is expected to reach $20.77 billion in 2026 at a CAGR of 7.99%.

CRACKING THE CANCER CODE: Avalon recently announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology – which is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer.

FDA APPROVALS: The company is headquartered in a hotbed and breeding ground for successful Biotech’s, which was responsible for a staggering 70 new FDA dr-ug approvals between 2020 and 2021.

PATENTS: Avalon has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology.

REMARKABLE SECTOR GROWTH: Based on worldwide sales forecasts from Evaluate Pharma, including both approved drugs and ones forecast to be approved, it is expected that conventional drug sales will grow at a compound annual growth rate (CAGR) of 6% from 2021 to 2026 and biologic sales excluding cell and gene therapies are forecast to grow from $415 billion to $541 billion, a CAGR of 5%. Cell and gene therapies, in comparison, are expected to grow from $4 billion a year in sales to over $45 billion over that same period, a significantly higher CAGR of 63%.



The next small float biotech locked and loaded!

20 EMA is ready to cross the 50 EMA, which sets up a bullish short swing opportunity.

MACD golden cross on 4 hour chart.

The average gains over the past six months on this same crossover on 4 hour time frame was over 60% in the average span of 3 to 5 days!


Watch for a volume over 8k the first hour of market open for possible move, and over 100k on daily close.

Volume will precede the move, key indication of our push coming and an impulsive break over 3.21 is our confirmation.


Day to Week: $3.46 (+10%)

1 Week: $3.86 (+20%)

1 to 2 Weeks: $4.29 (+30%)

2 Weeks+: $5.88 (+85%)

WHO is avalon globocare corp. (nasdaq:ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as cell therapy related companion diagnostics.

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.

Avalon GloboCare Corp. (NASDAQ:ALBT) Is Headquartered In One Of The Country’s Hottest Breeding Grounds For Successful Biotechs

Avalon GloboCare Corp. (Nasdaq: ALBT) is headquartered in Freehold, New Jersey.

New Jersey’s biotechnology cluster has grown from a mere 30 companies in the early 1990s to approximately 3,200 establishments in the state today, with 46 of those firms responsible for a staggering 70 new FDA drug approvals between 2020 and 2021, according to the trade association BioNJ.

And several sources indicate that despite recent IPO and capital market challenges, the biotech cluster’s ascension continues.

Debbie Hart, president and CEO of BioNJ, says of the overall US/global biotech community: “The science is advancing by leaps and bounds, and it’s creating lots of opportunities, new companies, and new advances in therapies and treatments.”

“When you look at what happened during the global pandemic – how the industry can really save the world – [it’s] not an understatement. It just speaks to ability and the science.”

New Jersey’s specific biotech juggernaut partly stems from a constellation of cutting-edge advances in cell and gene therapy operating in tandem with a Garden State life sciences ecosystem replete with contract manufacturing and clinical research organizations, as well as specialized accountants, attorneys and other professionals who serve the industry.

Such a network is particularly important for the biotechnology community given the challenges it faces.

Dean J. Paranicas, president and CEO of the HealthCare Institute of New Jersey (HINJ), details the overall “high risk profile” for the biopharmaceutical industry: “There’s that challenge of having enough capital to develop your product, being able to get it through the regulatory cycle, and then commercializing [it] and getting it into the marketplace.”

Paranicas additionally explains that New Jersey firms have beneficial opportunities to coordinate with the state’s research institutions as well as with more established companies located here.

Also helping to lubricate the state’s growing industry is New Jersey’s proximity to Wall Street and, separately, a time-zone advantage, which facilitates business communication with locales as diverse as, say, California and the United Kingdom.

David Jin, M.D., Ph.D. – President and Chief Executive Officer of Avalon

“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,”

“Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”

“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer”


Avalon GloboCare Corp. (Nasdaq: ALBT) recently announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.

In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.

Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.

Avalon is applying the bioinformatics from the fusion gene map with the goal of accelerating the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The first diagnostic prototype is expected to enter clinical study and regulatory filing stage during Q3 of 2023. The fusion gene map technology also provides an unprecedented opportunity to identify and validate fusion gene products as potential novel therapeutic targets. Additionally, this gives us an opportunity to expand Avalon’s R&D pipeline and intellectual property portfolio.

The global leukemia therapeutics market is expected to grow from $13.88 billion in 2021 to $15.27 billion in 2022 at a compound annual growth rate (CAGR) of 10.07%. The leukemia therapeutics market is expected to reach $20.77 billion in 2026 at a CAGR of 7.99%.

The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities that are used for the treatment of leukemia. Leukemia is a type of blood cancer that starts in the bone marrow and proceeds to uncontrolled blood cell growth. The type treatment for leukemia depends on various factors such as age, overall health, type of leukemia, its current condition within the body and others.

The main treatment types in leukemia therapeutics are chemotherapy, immunotherapy, targeted therapy, and other treatments. Immunotherapy is a method of leukemia treatment that stimulates the body’s immune system to recognize and eliminate malignant cells.

These are used to treat acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and other type of leukemia using small molecules and biologics. The various end users of leukemia therapeutics are hospitals, homecare, specialty clinics, and other end-users.(42)

North America was the largest region in the leukemia therapeutics market in 2021. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.


Cell and Gene Therapies

This industry is expected to grow from $4 Billion per year in sales to over $45 Billion, a CAGR of 63%, in comparison to conventional drug sales are forecasted to have a CAGR of 6% through 2026, and biologic sales excluding cell and gene therapies are expected to have a CAGR of 5%.


  • Source 1:
  • Source 2:
  • Source 3:
  • Source 4:
  • Source 5:
  • Source 6:
  • Source 7:
  • Source 8:
  • Source 9:
  • Source 10:
  • Source 11:
  • Source 12:
  • Source 13:
  • Source 14:
  • Source 15:
  • Source 16:
  • Source 18:
  • Source 19:
  • Source 20:
  • Source 21:
  • Source 22:
  • Source 23:
  • Source 24:
  • Source 25:
  • Source 26:
  • Source 27:
  • Source 28:×406.jpg
  • Source 29:
  • Source 30:
  • Source 31:
  • Source 32:
  • Source 33:
  • Source 34:
  • Source 35:
  • Source 36:
  • Source 37:
  • Source 38:
  • Source 39:
  • Source 40:
  • Source 41:
  • Source 42:
  • Source 43:
  • Source 44:
  • Source 45:


Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Virtus Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications in incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation: Pursuant to an agreement between Virtus Media LLC and North Equities Corp, Virtus Media LLC has been hired for a period beginning on 10/11/22 and ending on 10/14/22 to publicly disseminate information about (OTC: KNRLF) via digital communications. We have been paid fifteen thousand USD via ACH Bank Transfer. Pursuant to an agreement between Virtus Media LLC and Lifewater media LLC, Virtus Media has been hired for a period beginning on 2023-02-10 and ending after 2023-02-15 to publicly disseminate information about NASDAQ: ALBT. We have been paid fifteen thousand dollars USD via ACH Bank Transfer.